45 results
Page 2 of 3
8-K
EX-99.1
w90h54j
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
goekg64s
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
vlknob7hvnn9
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
8-K
EX-99.1
1zhyzxknu1jezwz97
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
EX-99.1
iyka0
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
EX-99.1
rsx3hdcw
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
424B5
mrj dc0v6r
11 Sep 20
Prospectus supplement for primary offering
4:44pm
424B5
r5xjhtpg2ru98tcg
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
gixunejcq6g
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am
8-K
EX-99.1
iemam87p
7 May 20
Intra-cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:42am
8-K
EX-99.1
kgigi6p 72de
23 Mar 20
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
7:52am
8-K
EX-99.1
h1s17sym1k
2 Mar 20
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2019 Financial Results and Provides Corporate Update
7:43am
424B5
owlnt3zrmn9mj38t vx
8 Jan 20
Prospectus supplement for primary offering
5:06pm
8-K
EX-99.3
bf24yv
6 Jan 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4:52pm
424B5
723q1sxj
6 Jan 20
Prospectus supplement for primary offering
4:42pm
S-3ASR
gq2gs4hh pr0d
6 Jan 20
Automatic shelf registration
4:02pm
8-K
EX-99.1
urobs7bl
23 Dec 19
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
8:15am